HLA-A2 tumor associated antigen peptides and compositions
AssigneeOse Pharma International SA
InventorsJohn D. Fikes, Glenn Ishioka, Alessandro Sette, Robert W. Chesnut
Life of this patent
Estimating the term…
Abstract
A peptide or composition comprising at least one HLA-A2 epitope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53.
Claims20
A method of inhibiting cancer in a patient comprising administering a composition comprising a peptide comprising a cytotoxic T-cell lymphocyte (CTL) epitope KVFGSLAFV (SEQ ID NO:7) and a peptide comprising a CTL epitope YLSGADLNL (SEQ ID NO:8), each peptide being less than 15 amino acid residues in length, the composition further comprising at least three additional peptides, wherein each of said three peptides is less than 15 amino acid residues in length and comprises a CTL epitope selected from the group consisting of
- KLBPVQLWV (SEQ ID NO:6)
- SMPPPGTRV (SEQ ID NO:5)
- IMIGHLVGV (SEQ ID NO:9)
- LLTFWNPPV (SEQ ID NO:4)
- KVAEIVHFL (SEQ ID NO:10)
- RLLQETELV (SEQ ID NO:2), and
- YLQLVFGIEV (SEQ ID NO:3)
- to a patient bearing
- a) at least one allele of a HLA-A2 or HLA-A2 supertype, and
- b) a cancer expressing at least one of CEA, HER2, MAGE2, MAGE3 and p53.
A method of inhibiting cancer in a patient comprising administering a composition comprising a peptide comprising LLTFWNPPV (SEQ ID NO:4), KVFGSLAFV (SEQ ID NO:7), KLBPVQLWV (SEQ ID NO:6), SMPPPGTRV (SEQ ID NO:5), YLSGADLNL (SEQ ID NO:8), IMIGHLVGV (SEQ ID NO:9), KVAEIVHFL (SEQ ID NO:10), RLLQETELV (SEQ ID NO:2), YLQLVFGIEV (SEQ ID NO:3), aKXVAAWTLKAAA (SEQ ID NO:1), wherein “a” in SEQ ID NO:1 is any of D-alanine or L-alanine, X in SEQ ID NO:1 is any of cyclohexylalanine, phenylalanine or tyrosine and wherein “B” is an α-aminoisobutyric acid or cysteine to a patient bearing
- a) at least one allele of a HLA-A2 or HLA-A2 supertype, and
- b) a cancer expressing at least one of CEA, HER2, MAGE2, MAGE3 and p53.
A composition, comprising LLTFWNPPV (SEQ ID NO:4), KVFGSLAFV (SEQ ID NO:7), KLBPVQLWV (SEQ ID NO:6), SMPPPGTRV (SEQ ID NO:5), YLSGADLNL (SEQ ID NO:
- 8), IMIGHLVGV (SEQ ID NO:9), KVAEIVHFL (SEQ ID NO:10), RLLQETELV (SEQ ID NO:2), YLQLVFGIEV (SEQ ID NO:3), and aKXVAAWTLKAAa (SEQ ID NO:1), wherein a in SEQ ID NO:1 is any of D-alanine or L-alanine and wherein X in SEQ ID NO:1 is any of cyclohexylalanine, phenylalanine or tyrosine and wherein B in KLBPVQLWV is an α-aminoisobutyric acid.
Dependencies are inferred from the claim text.